Aripiprazole : A Treatment for Severe Coprolalia in Refractory Gilles de la Tourette SyndromeBEN DJEBARA, Mouna; WORBE, Yulia; SCHUPBACH, Michael et al.Movement disorders. 2008, Vol 23, Num 3, pp 438-440, issn 0885-3185, 3 p.Article

Taq1A polymorphism in the dopamine D2 receptor gene predicts brain metabolic response to aripiprazole in healthy male volunteersKIM, Euitae; JUN SOO KWON; JANG, In-Jin et al.Pharmacogenetics and genomics (Print). 2008, Vol 18, Num 2, pp 91-97, issn 1744-6872, 7 p.Article

HOMER SPLICE VARIANTS MODULATION WITHIN CORTICO-SUBCORTICAL REGIONS BY DOPAMINE D₂ ANTAGONISTS, A PARTIAL AGONIST, AND AN INDIRECT AGONIST : IMPLICATION FOR GLUTAMATERGIC POSTSYNAPTIC DENSITY IN ANTIPSYCHOTICS ACTIONTOMASETTI, C; DELL'AVERSANO, C; IASEVOLI, F et al.Neuroscience. 2007, Vol 150, Num 1, pp 128-142, issn 0306-4522, 15 p.Article

Aripiprazole possibly worsens psychosisRAMASWAMY, Sriram; VIJAY, Dewan; WILLIAM, Marcil et al.International clinical psychopharmacology. 2004, Vol 19, Num 1, pp 45-48, issn 0268-1315, 4 p.Article

Protective effect of aripiprazole against glutamate cytotoxicity in dopaminergic neurons of rat mesencephalic culturesMATSUO, Takaaki; IZUMI, Yasuhiko; KUME, Toshiaki et al.Neuroscience letters. 2010, Vol 481, Num 2, pp 78-81, issn 0304-3940, 4 p.Article

Augmentation of aripiprazole with low-dose clozapineSTONER, Steven C; DAHMEN, Megan M; BERGES, Arnaldo et al.Pharmacotherapy. 2007, Vol 27, Num 11, pp 1599-1602, issn 0277-0008, 4 p.Article

Benefits of combining aripiprazole to clozapine : Three case reportsROCHA, Fabio Lopes; HARA, Claudia.Progress in neuro-psychopharmacology & biological psychiatry. 2006, Vol 30, Num 6, pp 1167-1169, issn 0278-5846, 3 p.Article

Aripiprazole and neuroleptic malignant syndromeCHAKRABORTY, Nandini; JOHNSTON, Timothy.International clinical psychopharmacology. 2004, Vol 19, Num 6, pp 351-353, issn 0268-1315, 3 p.Article

Bifeprunox and aripiprazole suppress in vivo VTA dopaminergic neuronal activity via D₂ and not D₃ dopamine autoreceptor activationETIEVANT, Adeline; BETRY, Cécile; ARNT, Jørn et al.Neuroscience letters. 2009, Vol 460, Num 1, pp 82-86, issn 0304-3940, 5 p.Article

A prospective 6-month analysis of the naturalistic use of aripiprazole : factors predicting favourable outcomeTAYLOR, D; ATKINSON, J; FISCHETTI, C et al.Acta psychiatrica Scandinavica. 2007, Vol 116, Num 6, pp 461-466, issn 0001-690X, 6 p.Article

Tardive Dyskinesia and Other Movement Disorders Secondary to AripiprazoleSIERRA PENA, Maria; YALTHO, Toby C; JANKOVIC, Joseph et al.Movement disorders. 2011, Vol 26, Num 1, pp 147-152, issn 0885-3185, 6 p.Article

Aripiprazole in treatment of borderline patients, part II: an 18-month follow-upNICKEL, Marius K; LOEW, Thomas H; PEDROSA GIL, Francisco et al.Psychopharmacologia. 2007, Vol 191, Num 4, pp 1023-1029, issn 0033-3158, 7 p.Article

Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacologySHAPIRO, David A; RENOCK, Sean; ARRINGTON, Elaine et al.Neuropsychopharmacology (New York, NY). 2003, Vol 28, Num 8, pp 1400-1411, issn 0893-133X, 12 p.Article

Strategies for Transitioning Therapy to Aripiprazole from Other Antipsychotics in SchizophreniaWISNIEWSKI, Christopher S; ROBERT, Sophie.The Annals of pharmacotherapy. 2012, Vol 46, Num 7-8, pp 1097-1104, issn 1060-0280, 8 p.Article

Is clozapine-aripiprazole combination a useful regime in the management of treatment-resistant schizophrenia?KARUNAKARAN, Kanapathippillai; TUNGARAZA, Tongeji E; HARBORNE, Giles C et al.Journal of psychopharmacology (Oxford). 2007, Vol 21, Num 4, pp 453-456, issn 0269-8811, 4 p.Article

Aripiprazole and its human metabolite are partial agonists at the human dopamine D₂ receptor, but the rodent metabolite displays antagonist propertiesWOOD, Martyn D; SCOTT, Claire; FORBES, Ian T et al.European journal of pharmacology. 2006, Vol 546, Num 1-3, pp 88-94, issn 0014-2999, 7 p.Article

Aripiprazole: A comprehensive review of its pharmacology, clinical efficacy, and tolerabilityDELEON, Anthony; PATEL, Nick C; CRISMON, M. Lynn et al.Clinical therapeutics. 2004, Vol 26, Num 5, pp 649-666, issn 0149-2918, 18 p.Article

Neuroleptic Malignant Syndrome with Aripiprazole in Huntington's DiseaseGAHR, Maximilian; ORTH, Michael; ABLER, Birgit et al.Movement disorders. 2010, Vol 25, Num 14, pp 2475-2476, issn 0885-3185, 2 p.Article

Advances in atypical antipsychotics for the treatment of schizophrenia: New formulations and new agentsKELLEHER, James P; CENTORRINO, Franca; ALBERT, Matthew J et al.CNS drugs. 2002, Vol 16, Num 4, pp 249-261, issn 1172-7047Article

Unique pharmacological profile of aripiprazole as the phasic component busterHAMAMURA, Takashi; HARADA, Toshiki.Psychopharmacologia. 2007, Vol 191, Num 3, pp 741-743, issn 0033-3158, 3 p.Article

AripiprazoleMCGAVIN, Jane K; GOA, Karen L.CNS drugs. 2002, Vol 16, Num 11, pp 779-786, issn 1172-7047, 8 p.Article

Efficacy of Aripiprazole in Comorbid Addiction in Bipolar DisorderALEXIS GEOFFROY, Pierre; GODDEFROY, Guillaume; ROLLAND, Benjamin et al.CNS neuroscience & therapeutics (Print). 2012, Vol 18, Num 4, pp 359-360, issn 1755-5930, 2 p.Article

Lack of Correlation Between the Steady-State Plasma Concentrations of Aripiprazole and Haloperidol in Japanese Patients With SchizophreniaNAKAMURA, Akifumi; MIHARA, Kazuo; NEMOTO, Kenji et al.Therapeutic drug monitoring. 2014, Vol 36, Num 6, pp 815-818, issn 0163-4356, 4 p.Article

Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: An open-label, parallel-arm, multiple-dose studyMALLIKAARJUN, Suresh; KANE, John M; BRICMONT, Patricia et al.Schizophrenia research. 2013, Vol 150, Num 1, pp 281-288, issn 0920-9964, 8 p.Article

Effect of adjunctive treatment with aripiprazole to atypical antipsychotics on cognitive function in schizophrenia patientsYASUI-FURUKORI, Norio; KANEDA, Ayako; SUGAWARA, Norio et al.Journal of psychopharmacology (Oxford). 2012, Vol 26, Num 6, pp 806-812, issn 0269-8811, 7 p.Article